A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia – investor.lilly.com

Breakthrough in Cholesterol Management: Lilly's VERVE-102 Shows Remarkable Results In a significant advancement for cardiovascular health, Eli Lilly announced promising results from a recent study highlighting the efficacy of VERVE-102,...